Concepts (164)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Cirrhosis | 18 | 2022 | 1003 | 3.980 |
Why?
|
| Liver Transplantation | 16 | 2024 | 1169 | 1.780 |
Why?
|
| End Stage Liver Disease | 6 | 2020 | 186 | 1.580 |
Why?
|
| Carcinoma, Hepatocellular | 16 | 2022 | 2160 | 1.140 |
Why?
|
| Quality Indicators, Health Care | 5 | 2024 | 376 | 0.990 |
Why?
|
| Waiting Lists | 8 | 2024 | 275 | 0.920 |
Why?
|
| Liver Neoplasms | 15 | 2022 | 4793 | 0.810 |
Why?
|
| Hepatitis C, Chronic | 4 | 2019 | 461 | 0.790 |
Why?
|
| Insurance, Health | 2 | 2019 | 262 | 0.720 |
Why?
|
| Social Discrimination | 1 | 2019 | 6 | 0.700 |
Why?
|
| Antiviral Agents | 4 | 2019 | 1261 | 0.690 |
Why?
|
| Tissue Donors | 3 | 2017 | 800 | 0.640 |
Why?
|
| Reimbursement Mechanisms | 1 | 2019 | 82 | 0.630 |
Why?
|
| Health Equity | 1 | 2019 | 57 | 0.620 |
Why?
|
| alpha-Fetoproteins | 4 | 2021 | 250 | 0.600 |
Why?
|
| Liver Diseases | 1 | 2022 | 597 | 0.560 |
Why?
|
| Patient Reported Outcome Measures | 3 | 2022 | 844 | 0.550 |
Why?
|
| Disease Management | 2 | 2014 | 1116 | 0.540 |
Why?
|
| Quality Improvement | 2 | 2022 | 933 | 0.540 |
Why?
|
| Cost of Illness | 3 | 2018 | 511 | 0.500 |
Why?
|
| Patient Selection | 5 | 2019 | 2104 | 0.500 |
Why?
|
| Models, Theoretical | 2 | 2019 | 794 | 0.500 |
Why?
|
| Frailty | 4 | 2021 | 130 | 0.490 |
Why?
|
| Ascites | 3 | 2019 | 210 | 0.440 |
Why?
|
| Drug Approval | 1 | 2014 | 183 | 0.430 |
Why?
|
| Health Services Administration | 1 | 2012 | 13 | 0.430 |
Why?
|
| United States | 17 | 2024 | 16313 | 0.410 |
Why?
|
| Tissue and Organ Procurement | 2 | 2012 | 240 | 0.400 |
Why?
|
| Retirement | 1 | 2012 | 22 | 0.400 |
Why?
|
| Patient Readmission | 1 | 2017 | 597 | 0.400 |
Why?
|
| Quality of Health Care | 2 | 2014 | 643 | 0.370 |
Why?
|
| Interdisciplinary Communication | 1 | 2012 | 278 | 0.370 |
Why?
|
| Hepatitis C | 2 | 2019 | 532 | 0.350 |
Why?
|
| Hospitals, Veterans | 1 | 2012 | 411 | 0.340 |
Why?
|
| Quality of Life | 2 | 2022 | 4734 | 0.320 |
Why?
|
| Resource Allocation | 1 | 2008 | 68 | 0.320 |
Why?
|
| Policy Making | 1 | 2008 | 85 | 0.310 |
Why?
|
| Liver Failure | 1 | 2008 | 142 | 0.290 |
Why?
|
| Public Health | 1 | 2009 | 303 | 0.290 |
Why?
|
| Quality Assurance, Health Care | 1 | 2011 | 600 | 0.270 |
Why?
|
| Medicare | 1 | 2012 | 934 | 0.270 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2014 | 1355 | 0.270 |
Why?
|
| Humans | 43 | 2024 | 270605 | 0.260 |
Why?
|
| Health Personnel | 1 | 2011 | 644 | 0.260 |
Why?
|
| Caregivers | 1 | 2012 | 731 | 0.250 |
Why?
|
| Early Detection of Cancer | 1 | 2012 | 1342 | 0.240 |
Why?
|
| Graft Rejection | 1 | 2008 | 846 | 0.230 |
Why?
|
| Hepatic Encephalopathy | 3 | 2019 | 75 | 0.210 |
Why?
|
| Delphi Technique | 2 | 2024 | 269 | 0.200 |
Why?
|
| Biomarkers | 1 | 2012 | 5149 | 0.190 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 2 | 2012 | 175 | 0.180 |
Why?
|
| Civil Rights | 1 | 2019 | 9 | 0.180 |
Why?
|
| Policy | 1 | 2019 | 53 | 0.170 |
Why?
|
| Prisoners | 1 | 2019 | 37 | 0.170 |
Why?
|
| Religion | 1 | 2019 | 95 | 0.160 |
Why?
|
| Risk Factors | 9 | 2021 | 17996 | 0.160 |
Why?
|
| Patient-Centered Care | 1 | 2022 | 323 | 0.160 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2018 | 46 | 0.160 |
Why?
|
| Time Factors | 9 | 2019 | 13229 | 0.150 |
Why?
|
| Practice Guidelines as Topic | 1 | 2008 | 2484 | 0.150 |
Why?
|
| Acute-On-Chronic Liver Failure | 1 | 2018 | 62 | 0.150 |
Why?
|
| Markov Chains | 4 | 2010 | 181 | 0.140 |
Why?
|
| Clinical Decision-Making | 2 | 2018 | 556 | 0.140 |
Why?
|
| Alcoholism | 1 | 2019 | 321 | 0.140 |
Why?
|
| Donor Selection | 1 | 2017 | 109 | 0.140 |
Why?
|
| Liver | 2 | 2020 | 2992 | 0.130 |
Why?
|
| Alcohol Drinking | 1 | 2019 | 590 | 0.130 |
Why?
|
| Point-of-Care Systems | 1 | 2018 | 216 | 0.130 |
Why?
|
| Health Services Needs and Demand | 1 | 2017 | 253 | 0.120 |
Why?
|
| Male | 18 | 2020 | 127509 | 0.120 |
Why?
|
| Adult | 14 | 2021 | 80769 | 0.120 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 887 | 0.120 |
Why?
|
| Decision Support Techniques | 2 | 2018 | 637 | 0.120 |
Why?
|
| Health Care Reform | 1 | 2014 | 70 | 0.120 |
Why?
|
| Female | 18 | 2020 | 147401 | 0.120 |
Why?
|
| Neuropsychological Tests | 1 | 2018 | 1153 | 0.110 |
Why?
|
| Health Status | 2 | 2018 | 610 | 0.110 |
Why?
|
| Bile Duct Diseases | 1 | 2012 | 47 | 0.100 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 1 | 2011 | 24 | 0.100 |
Why?
|
| Palliative Care | 1 | 2022 | 2149 | 0.090 |
Why?
|
| Disability Evaluation | 1 | 2012 | 233 | 0.090 |
Why?
|
| Middle Aged | 13 | 2020 | 89520 | 0.090 |
Why?
|
| Benchmarking | 2 | 2022 | 290 | 0.090 |
Why?
|
| Databases, Factual | 2 | 2018 | 2309 | 0.080 |
Why?
|
| Population Surveillance | 1 | 2012 | 641 | 0.080 |
Why?
|
| Predictive Value of Tests | 5 | 2018 | 5012 | 0.080 |
Why?
|
| Aged | 9 | 2019 | 72892 | 0.080 |
Why?
|
| Benzenesulfonates | 1 | 2010 | 196 | 0.080 |
Why?
|
| Cholestasis | 1 | 2011 | 208 | 0.080 |
Why?
|
| Medicaid | 1 | 2012 | 312 | 0.080 |
Why?
|
| Drug Therapy, Combination | 1 | 2014 | 2341 | 0.080 |
Why?
|
| Self Care | 1 | 2010 | 229 | 0.080 |
Why?
|
| Prevalence | 2 | 2018 | 3393 | 0.080 |
Why?
|
| Clinical Competence | 1 | 2017 | 1367 | 0.080 |
Why?
|
| Viral Load | 1 | 2009 | 486 | 0.070 |
Why?
|
| Medical Informatics | 1 | 2010 | 197 | 0.070 |
Why?
|
| Hospitalization | 1 | 2017 | 2217 | 0.070 |
Why?
|
| Patient Participation | 1 | 2011 | 476 | 0.070 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 2040 | 0.070 |
Why?
|
| Incidence | 3 | 2012 | 5883 | 0.070 |
Why?
|
| Health Behavior | 1 | 2011 | 616 | 0.070 |
Why?
|
| Retrospective Studies | 7 | 2019 | 39678 | 0.070 |
Why?
|
| Hepacivirus | 1 | 2009 | 405 | 0.070 |
Why?
|
| Algorithms | 1 | 2018 | 3974 | 0.070 |
Why?
|
| Health Care Costs | 1 | 2012 | 718 | 0.070 |
Why?
|
| Severity of Illness Index | 4 | 2019 | 4436 | 0.070 |
Why?
|
| Comorbidity | 1 | 2012 | 2436 | 0.060 |
Why?
|
| Young Adult | 5 | 2018 | 22221 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2011 | 15238 | 0.060 |
Why?
|
| Surveys and Questionnaires | 3 | 2012 | 5943 | 0.060 |
Why?
|
| Survival Rate | 2 | 2008 | 12469 | 0.060 |
Why?
|
| Graft Survival | 1 | 2008 | 1093 | 0.060 |
Why?
|
| Chronic Disease | 1 | 2010 | 1858 | 0.060 |
Why?
|
| Mass Screening | 1 | 2012 | 1571 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2011 | 1280 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2012 | 5989 | 0.050 |
Why?
|
| Pyridines | 1 | 2010 | 1299 | 0.050 |
Why?
|
| Michigan | 2 | 2012 | 71 | 0.050 |
Why?
|
| Treatment Outcome | 5 | 2019 | 34259 | 0.050 |
Why?
|
| Risk Assessment | 3 | 2019 | 7084 | 0.050 |
Why?
|
| Disease Progression | 2 | 2011 | 6865 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2019 | 10288 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2012 | 13329 | 0.040 |
Why?
|
| Registries | 2 | 2018 | 2300 | 0.040 |
Why?
|
| Protective Factors | 1 | 2019 | 109 | 0.040 |
Why?
|
| Sustained Virologic Response | 1 | 2019 | 61 | 0.040 |
Why?
|
| Karnofsky Performance Status | 1 | 2018 | 176 | 0.040 |
Why?
|
| North America | 1 | 2019 | 336 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2012 | 30806 | 0.040 |
Why?
|
| Preoperative Care | 1 | 2024 | 1554 | 0.040 |
Why?
|
| Canada | 1 | 2019 | 438 | 0.040 |
Why?
|
| Sickness Impact Profile | 1 | 2018 | 138 | 0.040 |
Why?
|
| Patient Dropouts | 1 | 2017 | 90 | 0.040 |
Why?
|
| Prognosis | 3 | 2011 | 22349 | 0.040 |
Why?
|
| Mobile Applications | 1 | 2018 | 113 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2021 | 620 | 0.030 |
Why?
|
| Age Factors | 2 | 2017 | 5487 | 0.030 |
Why?
|
| Survivors | 2 | 2010 | 1031 | 0.030 |
Why?
|
| Ultrasonography | 2 | 2012 | 1927 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2011 | 5117 | 0.020 |
Why?
|
| Transplantation, Heterotopic | 1 | 2011 | 42 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2012 | 443 | 0.020 |
Why?
|
| Perception | 1 | 2011 | 356 | 0.020 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2010 | 242 | 0.020 |
Why?
|
| Survival Analysis | 2 | 2010 | 9301 | 0.020 |
Why?
|
| Niacinamide | 1 | 2010 | 423 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2010 | 14559 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2011 | 686 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2010 | 689 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2011 | 2296 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2011 | 773 | 0.020 |
Why?
|
| Phenylurea Compounds | 1 | 2010 | 599 | 0.020 |
Why?
|
| Sex Factors | 1 | 2011 | 2188 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2009 | 1540 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 980 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2009 | 748 | 0.020 |
Why?
|
| Logistic Models | 1 | 2011 | 3475 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 4342 | 0.010 |
Why?
|
| Infant | 1 | 2017 | 13886 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2017 | 16878 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2012 | 9447 | 0.010 |
Why?
|
| Adolescent | 1 | 2017 | 32427 | 0.010 |
Why?
|
| Child | 1 | 2017 | 30347 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2011 | 5815 | 0.010 |
Why?
|